Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain
Background: Many of the current treatments for chronic neuropathic pain have variable effectiveness and known side effects. Given the prevalence of this type of intractable pain (3-17% of general population), additional therapeutic non-invasive approaches are desired. Magnetic Peripheral Nerve Stimu...
Gespeichert in:
Veröffentlicht in: | Journal of pain research 2024-09, Vol.17, p.3167 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 3167 |
container_title | Journal of pain research |
container_volume | 17 |
creator | Kapural, Leonardo Patel, Janus Rosenberg, Jason Charles Li, Sean Amirdelfan, Kasra Bedder, Marshall |
description | Background: Many of the current treatments for chronic neuropathic pain have variable effectiveness and known side effects. Given the prevalence of this type of intractable pain (3-17% of general population), additional therapeutic non-invasive approaches are desired. Magnetic Peripheral Nerve Stimulation (mPNS) delivered at 0.5Hz provides an effective pain relief without side effects. The objective of this randomized, controlled, multi-site clinical trial was to compare long-term safety and efficacy of mPNS in patients with chronic, intractable, post-traumatic or post-surgical neuropathic pain to comprehensive Conventional Medical Management (CMM). Methods: A total of 65 patients with post-traumatic, post-surgical neuropathy were treated within a multicenter, randomized, clinical trial comparing the safety and effectiveness of mPNS + CMM to CMM alone. Patients were randomized 1:1 and followed through 90 days. The primary endpoint is a proportion of responders, 50% or greater reduction in pain at Day 90. The secondary endpoints included the European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) and Patient Global Impression of Change (PGIC). Results: At 3 months, 71% of subjects were considered responders (>50% pain relief) in the mPNS + CMM group vs 13% of subjects in the CMM group. The mPNS + CMM group had a mean reduction in VAS scores at Day 90 of 3.8 points (>50% reduction), while CMM showed less than a 1-point (0.7 point) mean reduction or ~10% reduction (p < 0.0001). The EQ-5D-3L score increased in the mPNS + CMM study group, whereas the CMM group showed no improvement in EQ-5D-3L at Day 90. PGIC responder rates were 80.6% and 4.3% at Day 90 for mPNS + CMM and CMM groups, respectively. Conclusion: mPNS + CMM was superior to CMM in a randomized prospective study when used for treatment of post-traumatic, post-surgical neuropathy. Due to the lack of other effective non-invasive treatments for neuropathic pain, mPNS should be considered much earlier in the treatment algorithm. Keywords: neuropathic pain, noninvasive, cost effective, pain relief, neuropathy |
doi_str_mv | 10.2147/JPR.S481944 |
format | Article |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A813513405</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A813513405</galeid><sourcerecordid>A813513405</sourcerecordid><originalsourceid>FETCH-LOGICAL-g675-b8dbb0cb7d351bcdd93761a67c19e3da07e00d0aeb65108b8e2d458bbab4b5073</originalsourceid><addsrcrecordid>eNptTMtKw0AUHUTBWl35AwOuE-8kk8xkGUp8UbTY7MudmTvtSJOUJIL9eyO66ELO4hzOi7FbAXEipLp_Wb3Ha6lFIeUZmwmhdKSggPMTfcmuhuEDINdJIWasWqOn8cixdbzyPli0R955Xn51La931OPhyH3X87onHBtqx5_0lT777oDjLli-wtBeswuP-4Fu_njO6oeqXjxFy7fH50W5jLa5yiKjnTFgjXJpJox1rkhVLjBXVhSUOgRFAA6QTJ4J0EZT4mSmjUEjTQYqnbO739st7mkTWt-NPdomDHZTajGdphKyqRX_05rgqAm2a8mHyT8ZfANU-Vtx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain</title><source>Taylor & Francis Open Access</source><source>DOVE Medical Press Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Kapural, Leonardo ; Patel, Janus ; Rosenberg, Jason Charles ; Li, Sean ; Amirdelfan, Kasra ; Bedder, Marshall</creator><creatorcontrib>Kapural, Leonardo ; Patel, Janus ; Rosenberg, Jason Charles ; Li, Sean ; Amirdelfan, Kasra ; Bedder, Marshall</creatorcontrib><description>Background: Many of the current treatments for chronic neuropathic pain have variable effectiveness and known side effects. Given the prevalence of this type of intractable pain (3-17% of general population), additional therapeutic non-invasive approaches are desired. Magnetic Peripheral Nerve Stimulation (mPNS) delivered at 0.5Hz provides an effective pain relief without side effects. The objective of this randomized, controlled, multi-site clinical trial was to compare long-term safety and efficacy of mPNS in patients with chronic, intractable, post-traumatic or post-surgical neuropathic pain to comprehensive Conventional Medical Management (CMM). Methods: A total of 65 patients with post-traumatic, post-surgical neuropathy were treated within a multicenter, randomized, clinical trial comparing the safety and effectiveness of mPNS + CMM to CMM alone. Patients were randomized 1:1 and followed through 90 days. The primary endpoint is a proportion of responders, 50% or greater reduction in pain at Day 90. The secondary endpoints included the European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) and Patient Global Impression of Change (PGIC). Results: At 3 months, 71% of subjects were considered responders (>50% pain relief) in the mPNS + CMM group vs 13% of subjects in the CMM group. The mPNS + CMM group had a mean reduction in VAS scores at Day 90 of 3.8 points (>50% reduction), while CMM showed less than a 1-point (0.7 point) mean reduction or ~10% reduction (p < 0.0001). The EQ-5D-3L score increased in the mPNS + CMM study group, whereas the CMM group showed no improvement in EQ-5D-3L at Day 90. PGIC responder rates were 80.6% and 4.3% at Day 90 for mPNS + CMM and CMM groups, respectively. Conclusion: mPNS + CMM was superior to CMM in a randomized prospective study when used for treatment of post-traumatic, post-surgical neuropathy. Due to the lack of other effective non-invasive treatments for neuropathic pain, mPNS should be considered much earlier in the treatment algorithm. Keywords: neuropathic pain, noninvasive, cost effective, pain relief, neuropathy</description><identifier>ISSN: 1178-7090</identifier><identifier>EISSN: 1178-7090</identifier><identifier>DOI: 10.2147/JPR.S481944</identifier><language>eng</language><publisher>Dove Medical Press Limited</publisher><subject>Care and treatment ; Health aspects ; Medical equipment and supplies industry ; Medical test kit industry ; Pain</subject><ispartof>Journal of pain research, 2024-09, Vol.17, p.3167</ispartof><rights>COPYRIGHT 2024 Dove Medical Press Limited</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Kapural, Leonardo</creatorcontrib><creatorcontrib>Patel, Janus</creatorcontrib><creatorcontrib>Rosenberg, Jason Charles</creatorcontrib><creatorcontrib>Li, Sean</creatorcontrib><creatorcontrib>Amirdelfan, Kasra</creatorcontrib><creatorcontrib>Bedder, Marshall</creatorcontrib><title>Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain</title><title>Journal of pain research</title><description>Background: Many of the current treatments for chronic neuropathic pain have variable effectiveness and known side effects. Given the prevalence of this type of intractable pain (3-17% of general population), additional therapeutic non-invasive approaches are desired. Magnetic Peripheral Nerve Stimulation (mPNS) delivered at 0.5Hz provides an effective pain relief without side effects. The objective of this randomized, controlled, multi-site clinical trial was to compare long-term safety and efficacy of mPNS in patients with chronic, intractable, post-traumatic or post-surgical neuropathic pain to comprehensive Conventional Medical Management (CMM). Methods: A total of 65 patients with post-traumatic, post-surgical neuropathy were treated within a multicenter, randomized, clinical trial comparing the safety and effectiveness of mPNS + CMM to CMM alone. Patients were randomized 1:1 and followed through 90 days. The primary endpoint is a proportion of responders, 50% or greater reduction in pain at Day 90. The secondary endpoints included the European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) and Patient Global Impression of Change (PGIC). Results: At 3 months, 71% of subjects were considered responders (>50% pain relief) in the mPNS + CMM group vs 13% of subjects in the CMM group. The mPNS + CMM group had a mean reduction in VAS scores at Day 90 of 3.8 points (>50% reduction), while CMM showed less than a 1-point (0.7 point) mean reduction or ~10% reduction (p < 0.0001). The EQ-5D-3L score increased in the mPNS + CMM study group, whereas the CMM group showed no improvement in EQ-5D-3L at Day 90. PGIC responder rates were 80.6% and 4.3% at Day 90 for mPNS + CMM and CMM groups, respectively. Conclusion: mPNS + CMM was superior to CMM in a randomized prospective study when used for treatment of post-traumatic, post-surgical neuropathy. Due to the lack of other effective non-invasive treatments for neuropathic pain, mPNS should be considered much earlier in the treatment algorithm. Keywords: neuropathic pain, noninvasive, cost effective, pain relief, neuropathy</description><subject>Care and treatment</subject><subject>Health aspects</subject><subject>Medical equipment and supplies industry</subject><subject>Medical test kit industry</subject><subject>Pain</subject><issn>1178-7090</issn><issn>1178-7090</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptTMtKw0AUHUTBWl35AwOuE-8kk8xkGUp8UbTY7MudmTvtSJOUJIL9eyO66ELO4hzOi7FbAXEipLp_Wb3Ha6lFIeUZmwmhdKSggPMTfcmuhuEDINdJIWasWqOn8cixdbzyPli0R955Xn51La931OPhyH3X87onHBtqx5_0lT777oDjLli-wtBeswuP-4Fu_njO6oeqXjxFy7fH50W5jLa5yiKjnTFgjXJpJox1rkhVLjBXVhSUOgRFAA6QTJ4J0EZT4mSmjUEjTQYqnbO739st7mkTWt-NPdomDHZTajGdphKyqRX_05rgqAm2a8mHyT8ZfANU-Vtx</recordid><startdate>20240930</startdate><enddate>20240930</enddate><creator>Kapural, Leonardo</creator><creator>Patel, Janus</creator><creator>Rosenberg, Jason Charles</creator><creator>Li, Sean</creator><creator>Amirdelfan, Kasra</creator><creator>Bedder, Marshall</creator><general>Dove Medical Press Limited</general><scope/></search><sort><creationdate>20240930</creationdate><title>Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain</title><author>Kapural, Leonardo ; Patel, Janus ; Rosenberg, Jason Charles ; Li, Sean ; Amirdelfan, Kasra ; Bedder, Marshall</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g675-b8dbb0cb7d351bcdd93761a67c19e3da07e00d0aeb65108b8e2d458bbab4b5073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Care and treatment</topic><topic>Health aspects</topic><topic>Medical equipment and supplies industry</topic><topic>Medical test kit industry</topic><topic>Pain</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kapural, Leonardo</creatorcontrib><creatorcontrib>Patel, Janus</creatorcontrib><creatorcontrib>Rosenberg, Jason Charles</creatorcontrib><creatorcontrib>Li, Sean</creatorcontrib><creatorcontrib>Amirdelfan, Kasra</creatorcontrib><creatorcontrib>Bedder, Marshall</creatorcontrib><jtitle>Journal of pain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kapural, Leonardo</au><au>Patel, Janus</au><au>Rosenberg, Jason Charles</au><au>Li, Sean</au><au>Amirdelfan, Kasra</au><au>Bedder, Marshall</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain</atitle><jtitle>Journal of pain research</jtitle><date>2024-09-30</date><risdate>2024</risdate><volume>17</volume><spage>3167</spage><pages>3167-</pages><issn>1178-7090</issn><eissn>1178-7090</eissn><abstract>Background: Many of the current treatments for chronic neuropathic pain have variable effectiveness and known side effects. Given the prevalence of this type of intractable pain (3-17% of general population), additional therapeutic non-invasive approaches are desired. Magnetic Peripheral Nerve Stimulation (mPNS) delivered at 0.5Hz provides an effective pain relief without side effects. The objective of this randomized, controlled, multi-site clinical trial was to compare long-term safety and efficacy of mPNS in patients with chronic, intractable, post-traumatic or post-surgical neuropathic pain to comprehensive Conventional Medical Management (CMM). Methods: A total of 65 patients with post-traumatic, post-surgical neuropathy were treated within a multicenter, randomized, clinical trial comparing the safety and effectiveness of mPNS + CMM to CMM alone. Patients were randomized 1:1 and followed through 90 days. The primary endpoint is a proportion of responders, 50% or greater reduction in pain at Day 90. The secondary endpoints included the European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) and Patient Global Impression of Change (PGIC). Results: At 3 months, 71% of subjects were considered responders (>50% pain relief) in the mPNS + CMM group vs 13% of subjects in the CMM group. The mPNS + CMM group had a mean reduction in VAS scores at Day 90 of 3.8 points (>50% reduction), while CMM showed less than a 1-point (0.7 point) mean reduction or ~10% reduction (p < 0.0001). The EQ-5D-3L score increased in the mPNS + CMM study group, whereas the CMM group showed no improvement in EQ-5D-3L at Day 90. PGIC responder rates were 80.6% and 4.3% at Day 90 for mPNS + CMM and CMM groups, respectively. Conclusion: mPNS + CMM was superior to CMM in a randomized prospective study when used for treatment of post-traumatic, post-surgical neuropathy. Due to the lack of other effective non-invasive treatments for neuropathic pain, mPNS should be considered much earlier in the treatment algorithm. Keywords: neuropathic pain, noninvasive, cost effective, pain relief, neuropathy</abstract><pub>Dove Medical Press Limited</pub><doi>10.2147/JPR.S481944</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1178-7090 |
ispartof | Journal of pain research, 2024-09, Vol.17, p.3167 |
issn | 1178-7090 1178-7090 |
language | eng |
recordid | cdi_gale_infotracmisc_A813513405 |
source | Taylor & Francis Open Access; DOVE Medical Press Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
subjects | Care and treatment Health aspects Medical equipment and supplies industry Medical test kit industry Pain |
title | Safety and Efficacy of Axon Therapy for Treatment of Neuropathic Pain |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T07%3A20%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Efficacy%20of%20Axon%20Therapy%20for%20Treatment%20of%20Neuropathic%20Pain&rft.jtitle=Journal%20of%20pain%20research&rft.au=Kapural,%20Leonardo&rft.date=2024-09-30&rft.volume=17&rft.spage=3167&rft.pages=3167-&rft.issn=1178-7090&rft.eissn=1178-7090&rft_id=info:doi/10.2147/JPR.S481944&rft_dat=%3Cgale%3EA813513405%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A813513405&rfr_iscdi=true |